Northern Exposure PR
We are the leading public relations company serving the life science, pharmaceutical and technology industries.Northern Exposure is the leading public relations company serving the life science, pharmaceutical and technology industries.
Twenty years experience maximising clients’ media exposure and advising on subjects from press handling, marketing strategy and reputation management
Northern Exposure Public Relations is uniquely skilled in assisting clients in all public relations requirements
Meet Our Team
Richard Kerns
Managing Director
Richard has twenty five years’ experience working with life science companies and organisations around the globe, both independently and within larger agencies.
Edward Dutton
Vice President
Ed has over fifteen years experience of working within the pharmaceutical industry, both as a laboratory chemist and in sales and marketing roles within contract research organisations, contract manufacturers and technology based companies.
Sarah Houlton
Technical Consultant in Residence
Sarah has a degree and PhD in chemistry from Imperial College London, and worked as a drug discovery chemist in the pharmaceutical industry. As a science journalist, she has been writing about the pharmaceutical, biotech and chemical industries for more than twenty years.
Our Services
NEPR can assist clients in numerous manners, either on a retained agency basis or through project work around events. Activities include:
Planning & research, web content creation, media relations, technical articles, thought leadership articles, trade show and event management and support, social media, product launches, crisis management & more.
Contact us today to find out how we can assist you
Our Clients
Client News
05/09/2019 Catalent to Open New Clinical Supply Facility in San Diego
12/09/2019 Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
17/09/2019 SGS Appoints Steven Thys as Director of Global Clinical Operations
14/11/2019 Cambrex Wins Third API Development Award at CPhI Worldwide
19/11/2019 Catalent Appoints Corporate Development and Science Leaders to Drive Growth and Innovation
21/11/2019 Catalent to Supply BeiGene’s BTK Inhibitor BRUKINSA™ (zanubrutinib)
04/12/2019 Cambrex Announces Completion of Acquisition by the Permira Funds
12/12/2019 Catalent Launches New CTSuccess™ Service to Guide Sponsors to Smarter Clinical Trial Supply Planning
06/01/2020 Cambrex Announces Management Changes and Board Appointments
07/01/2020 Catalent Completes Purchase of Biologics Fill-Finish and Oral Solid Dose Facility in Anagni, Italy
14/01/2020 Catalent Launches FlexDirect™ Direct-to-Patient Clinical Supply Services
16/01/2020 Catalent Further Strengthens Biologics Business with Key Senior Appointments
29/01/2020 Catalent Appoints Ricci Whitlow to Lead Clinical Supply Services Business
11/02/2020 Catalent and Zumutor Biologics Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
12/02/2020 Catalent Appoints Jim Walter as Vice President of Operations for Oral and Specialty Delivery
25/02/2020 Perrigo and Catalent Announce FDA Approval of Perrigo’s AB-Rated Generic Version of ProAir® HFA
27/02/2020 Catalent Announces Supplying Blueprint Medicines’ Precision Therapy AYVAKIT™ (avapritinib)
09/03/2020 Vectura appoints Mark Bridgewater as Chief Commercial Officer
17/03/2020 Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment
Upcoming Events
NEPR will be attending the following events:
CPhI North America
April 30–May 2, 2019
Chicago, IL
Healthcare Estates
October 8 – 9, 2019
Manchester, UK
CPhI Worldwide
November 5 – 7, 2019
Frankfurt, Germany
about 4 months ago | @NrthnExposurePR